Effects of Amlodipine on the Pharmacokinetics of Warfarin after Oral and Intravenous Administration of Warfarin in Rats
![]() ![]() |
Choi, Dong-Hyun
(College of Medicine, Chosun University)
Piao, Yong-Ji (Shenzhen Salubris Pharmaceuticals Co.) Choi, Eun-Joo (College of Pharmacy, Chosun University) Choi, Jun-Shik (College of Pharmacy, Chosun University) Burm, Jin-Pil (College of Nursing, Chosun Nursing College) |
1 | Stoysich, A. M., Lucas, B. D., Mohiuddin, S. M. and Hilleman, D. E. (1996) Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. Int. J. Clin. Pharmacol. Ther. 34, 56-60. |
2 | Wacher, V. J., Salphati, L. and Benet, L. Z. (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46, 89-102. DOI |
3 | Wallin, R., Sane, D. C. and Hutson, S. M. (2002) Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb. Res. 108, 221-226. DOI |
4 | Yusa, K. and Tsuruo, T. (1989) Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specifi c sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49, 5002-5006. |
5 | Zhu, M., Chan, K. W., Ng, L. S., Chang, Q., Chang, S. and Li. R. C. (1999) Possible infl uences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J. Pharm. Pharmacol. 51, 175-180. DOI ScienceOn |
6 | Hirsh, J., Dalen, J. E., Anderson, DR., Poller, L., Bussey, H., Ansell, J., Deykin, D. and Brandt, J. T. (1998) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114, 445-469. DOI |
7 | Holford, N. H. G. (1986) Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin. Pharmacokinet. 11, 483-504. DOI |
8 | Kaminsky, L. S. and Zhang, Z. Y. (1997) Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67-74. DOI |
9 | Kim, K. A., Park, P. W. and Park, J. Y. (2009) Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. Chirality 21, 485-491. DOI |
10 | Kungys, G., Naujoks, H. and Wanner, C. (2003) Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. Eur. J. Clin. Pharmacol. 59, 291-295. DOI |
11 | Meredith, P. A. and Elliott, H. L. (1992) Clinical pharmacokinetics of amlodipine. Clin. Pharmacokinet. 22, 22-31. DOI |
12 | Mungall, D. R. (1985) Population pharmacokinetics of racemic warfarin in adult patients. J. Pharmacokinet. Biopharm. 13, 213-227. DOI |
13 | Abernethy, D. R. (1992) Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology 80, 31-36. DOI |
14 | Nishio, S., Watanabe, H., Kosuge, K., Uchida, S., Hayashi, H. and Ohashi, K. (2005) Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens. Res. 28, 223-227. DOI |
15 | Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. (1993) P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett. 324, 99-102. DOI |
16 | Scordo, M. G., Pengo, V., Spina, E., Dahl, M. L., Gusella, M. and Padrini, R. (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 72, 702-710. DOI |
17 | Benet, L. Z., Cummins, C. L. and Wu, C. Y. (2003) Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. 4, 393-398. DOI |
18 | Choi, J. S., Piao, Y. J. and Han, H. K. (2006) Phatmacokinetics interaction between Fluvastatin and Diltiazem in rats. Biopharm. Drug Dispos. 27, 437-441. DOI |
19 | Choi, D. H., Chang, K. S., Hong, S. P. and Choi, J. S. (2008) Effect of atrovastatin on intravenous and oral pharmacokinetics of verapamil in rats. Biopharm. Drug Dispos. 29, 45-50. DOI |
20 | Crespi, C. L., Miller, V. P. and Penman, B. W. (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188-190. DOI |
21 | Cummins, C. L., Jacobsen, W. and Benet, L. Z. (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 300, 1036-1045. DOI |
22 | Abernethy, D. R., Kaminsky, L. S. and Dickinson, T. H. (1991) Selective inhibition of warfarin metabolism by diltiazem in humans. J. Pharmacol. Exp. Ther. 257, 411-415. |
23 | Darvari, R. and Boroujerdi, M. (2004) Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin - a comparison with tamoxifen. J. Pharm. Pharmacol. 56, 985-991. DOI ScienceOn |
24 | Han, C. Y., Cho, K. B., Choi, H. S., Han, H. K. and Kang, K. W. (2008) Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29, 1837-1844. DOI |
25 | Harmsze, A. M., Robijns, K., van Werkum ,J. W., Breet, N. J., Hackeng, C. M., Ten Berg, J. M., Ruven, H. J., Klungel, O. H., de Boer, A. and Deneer, V. H. (2010) The use of amlodipine, but not of Pglycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb. Haemost. 103, 920-925. DOI ScienceOn |
![]() |